EverBridge Group has reached an exclusive strategic cooperation with Pulmonx.

瑞桥鼎科集团是一家亚洲领先的医疗科技集团，致力于为全球客户提供尖端的高品质的和可负担的医疗技术，快速增长的产品组合涵盖外周血管神经科学和肿瘤三大领域，并依托五大专业研发和精益生产中心，在球囊、导管、支架、表面处理和有源设备领域提供一流的OEM/ODM服务。     

我们与来自全球的优秀企业开展广泛合作，为亚洲和世界的医疗科技创新搭建桥梁，为全球的医生和患者提供更好的治疗选择。

EverBridge Group is a leading MedTech company in Asia, committed to providing high-quality and affordable products to global customers.

We engage in extensive collaboration with outstanding companies around the world, establishing a bridge for medical technology innovation between Asia and the world, and providing better treatment options for doctors and patients worldwide.

Pulmonx是慢性阻塞性肺病 (COPD) 微创治疗领域的全球领导者，其Zephyr支气管活瓣、Chartis 肺部评估系统和 StratX 肺部分析平台旨在评估和治疗经医疗管理但仍有严重肺气肿的COPD患者。Zephyr 支气管活瓣于 2018 年 6 月被美国FDA批准为“突破性器械”。

Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” (The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines.)